STOCK TITAN

BioNTech SE American Depositary Share - BNTX STOCK NEWS

Welcome to our dedicated page for BioNTech SE American Depositary Share news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE American Depositary Share stock.

BioNTech SE (American Depositary Share - BNTX) is a leading biotechnology company based in Germany, renowned for its pioneering work in the field of immunotherapy and vaccines. BioNTech's core business revolves around developing innovative cancer treatments and vaccines for infectious diseases, including the widely recognized COVID-19 vaccine, Comirnaty, which it co-developed with Pfizer.

BioNTech's oncology pipeline encompasses several advanced drug classes, including mRNA-based drugs that encode antigens, neoantigens, cytokines, and antibodies. The company is also advancing cell therapies, bispecific antibodies, and antibody-drug conjugates, positioning itself at the forefront of cancer treatment innovation.

Partnerships play a crucial role in BioNTech's strategy. The company collaborates with major pharmaceutical giants such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, leveraging shared expertise to accelerate the development and commercialization of its therapies. Recent strategic collaborations include an agreement with MediLink Therapeutics to utilize their TMALIN® antibody-drug conjugate platform, enhancing BioNTech's capabilities in targeting novel cancer therapeutics.

BioNTech's financial health is robust, bolstered by the commercial success of Comirnaty and ongoing strategic partnerships. The company's commitment to innovation and excellence is reflected in its continuous efforts to develop new therapeutics and vaccines, ensuring significant contributions to global healthcare.

For more detailed information, visit the company's official website at www.BioNTech.com.

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) is set to announce its financial results for the fourth quarter of 2020 on March 30, 2021. An investor call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CET) to discuss the results and provide a corporate update. The event will be accessible via the company’s website. BioNTech specializes in immunotherapy for cancer and serious diseases, leveraging mRNA technology and collaborating with major pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
conferences earnings
-
Rhea-AI Summary

The Israel Ministry of Health, Pfizer, and BioNTech released data showing significantly lower COVID-19 incidences in fully vaccinated individuals with the Pfizer-BioNTech vaccine. Findings indicate vaccinated individuals were 44 times less likely to develop symptomatic COVID-19 and 29 times less likely to die. Vaccine effectiveness was measured at 97% against symptomatic cases and severe outcomes, and 94% against asymptomatic infections. This comprehensive evidence supports ongoing global vaccination efforts amidst the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
covid-19
-
Rhea-AI Summary

The Israel Ministry of Health, Pfizer, and BioNTech announced significant findings from a real-world study showing a 97% effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in preventing symptomatic COVID-19, severe cases, and deaths. This data, derived from health surveillance from January to March 2021, showcases the impact of Israel's vaccination efforts, particularly against the B.1.1.7 variant. Further, the vaccine demonstrated 94% effectiveness against asymptomatic infections, emphasizing its role in controlling the pandemic and supporting ongoing immunization campaigns globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
covid-19
Rhea-AI Summary

Pfizer and BioNTech have initiated a Phase 1/2/3 trial to evaluate a third dose of their COVID-19 vaccine, BNT162b2, aimed at studying safety and immunogenicity against evolving SARS-CoV-2 variants. Participants who received the initial two doses will be offered a booster dose 6 to 12 months later. They are also in discussions with regulatory authorities for a variant-specific mRNA vaccine, potentially targeting the B.1.351 lineage. The companies seek to ensure robust immunity and prepare for possible future vaccine adaptations, with ongoing assessments expected over two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
covid-19
-
Rhea-AI Summary

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) are evaluating a third dose of their COVID-19 vaccine, BNT162b2, to assess safety and immunity against circulating and emerging SARS-CoV-2 variants. This study will involve participants from a previous Phase 1 trial, who will receive the booster 6 to 12 months post-initial vaccination. Additionally, the companies are in talks with the FDA and EMA for a clinical study on a variant-specific vaccine. The goal is to ensure preparedness against future variants while maintaining current vaccine effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
covid-19
-
Rhea-AI Summary

BioNTech (BNTX) and Pfizer have submitted data to the FDA to update the Emergency Use Authorization for their COVID-19 vaccine. The proposed change would allow the vaccine to be stored at -25°C to -15°C for up to two weeks, providing better logistical flexibility for pharmacies and vaccination centers. This submission includes stability data from the last nine months of development. The current storage requirement necessitates ultra-cold temperatures between -80ºC and -60ºC. If approved, the updated storage guidelines would enhance accessibility for vaccine distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
covid-19
Rhea-AI Summary

Pfizer and BioNTech have initiated a global Phase 2/3 trial for their COVID-19 vaccine (BNT162b2) involving about 4,000 healthy pregnant women in several countries, including the U.S. and U.K. The trial aims to assess the vaccine's safety and immunogenicity in this vulnerable group. Participants will be unblinded post-delivery, allowing those who received a placebo to be vaccinated. The trial follows prior studies indicating no reproductive toxicity in animals. This initiative marks a step towards ensuring vaccine safety for crucial populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
clinical trial covid-19
-
Rhea-AI Summary

On February 17, 2021, Pfizer and BioNTech released findings from an in vitro study confirming the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) neutralizes the South African variant of SARS-CoV-2. Despite reduced neutralization against the variant's mutations, all sera tested effectively neutralized the variant. No evidence suggests that the variant escapes protection from the vaccine in vaccinated individuals. The companies are evaluating other variants and preparing for a potential updated mRNA vaccine. The vaccine is under Emergency Use Authorization in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
covid-19
-
Rhea-AI Summary

Pfizer and BioNTech have secured a new agreement with the European Commission to deliver an additional 200 million doses of the COMIRNATY vaccine, bringing the total supply to 500 million doses by the end of 2021. The agreement allows for an option of 100 million more doses. With this arrangement, at least 250 million Europeans could be vaccinated. Both companies are ramping up manufacturing capacity to meet global demand, aiming for around two billion doses by the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Rhea-AI Summary

The U.S. government has exercised its option to purchase an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine, bringing the total to 300 million. The government will pay $1.95 billion for these doses, aimed at vaccinating 150 million people. Pfizer and BioNTech are committed to increasing vaccine supply to combat COVID-19. The vaccine has been authorized for emergency use in individuals aged 16 and older. Manufacturing primarily occurs at Pfizer's Kalamazoo facility, utilizing BioNTech's proprietary mRNA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
covid-19

FAQ

What is the current stock price of BioNTech SE American Depositary Share (BNTX)?

The current stock price of BioNTech SE American Depositary Share (BNTX) is $113.08 as of December 20, 2024.

What is the market cap of BioNTech SE American Depositary Share (BNTX)?

The market cap of BioNTech SE American Depositary Share (BNTX) is approximately 27.0B.

What does BioNTech SE do?

BioNTech SE is a biotechnology company focused on developing cancer immunotherapies and vaccines for infectious diseases, including COVID-19.

Where is BioNTech SE based?

BioNTech SE is based in Germany.

What is BioNTech's most well-known product?

BioNTech's most well-known product is the COVID-19 vaccine, Comirnaty, developed in collaboration with Pfizer.

Who are BioNTech's major partners?

BioNTech collaborates with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab.

What types of cancer therapies is BioNTech developing?

BioNTech is developing a variety of cancer therapies, including mRNA-based drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates.

What is the TMALIN® platform?

The TMALIN® platform is an antibody-drug conjugate technology developed by MediLink Therapeutics, used by BioNTech for cancer therapeutics.

How can investors find more information about BioNTech?

Investors can find more information on BioNTech's official website or by contacting their investor relations team.

What recent collaboration has BioNTech announced?

BioNTech recently announced a strategic collaboration with MediLink Therapeutics to use their TMALIN® antibody-drug conjugate platform for novel cancer targets.

What is BioNTech's role in the fight against COVID-19?

BioNTech developed the COVID-19 vaccine Comirnaty in collaboration with Pfizer, which has become a critical tool in combating the pandemic.

Where can I find BioNTech's latest news and updates?

BioNTech's latest news and updates can be found on their official website and through their media relations contacts.

BioNTech SE American Depositary Share

Nasdaq:BNTX

BNTX Rankings

BNTX Stock Data

26.95B
91.82M
61.66%
20.63%
1.03%
Biotechnology
Healthcare
Link
United States of America
Mainz